News and Announcements
Viralytics Ltd (ASX:VLA) – Shareholder and Investor Presentation
- Published April 03, 2013 12:07PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Viralytics Ltd (ASX:VLA) is an Australian ASX listed biotechnology cancer company focussed on developing viruses which selectively target cancer cells.
OVIERVIEW:
- Lead product is CAVATAK™ with broad anti-cancer activity
- CAVATAK™ program:
- Completed five Australian Phase 1 trials with 28 patients
- Current US Phase 2 trial in melanoma patients
- Planned Phase 1/2 UK trial in lung, prostate, bladder and melanoma cancer patients
- Potential low toxicity unlike traditional chemotherapies
- Achieved GMP manufacture
- Robust intellectual property/patent portfolio
- Big Pharma interest: 2011 US$1.0 billion Amgen/Biovex deal
- One of only 2 listed oncolytic virus companies globally
- Experienced Board/Management and Scientific team
To read the full ASX announcement, please download the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
